Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

KDventures

0.23 SEK-8.58 %15.10, 17.29
Less than 1K followers

KDV B

NASDAQ Stockholm

Investment

Financials

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
-8.58 %
-12.50 %
-5.63 %
-10.67 %
-33.94 %
-67.23 %
-81.63 %
-91.33 %
-99.19 %

KDventures is an investment company focused on long-term equity investments in biotechnology and pharmaceutical companies. The company's goal is to develop promising medical innovations stemming from academic research at Karolinska Institutet and other universities in the Nordic region. The company's portfolio includes companies in sectors such as biotechnology and medical technology. KDventures was founded in 2003 and is headquartered in Solna, Sweden.

Read more
Market cap
178M SEK
Turnover
781.77K SEK
Revenue
1.67M
EBIT %
-11,617.24 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
All
Press releases
ShowingAll content types

Financial calendar
13.11
2026

Interim report Q3'26

12.2
2027

Annual report '26

29.4
2027

Interim report Q1'27

Regulatory press release15.10.2026, 17.00

John Öhd focuses on Modus Therapeutics and continues as Senior Advisor to KDventures

KDventures
Press release15.10.2026, 15.42

Redeye: KDventures: Safety Pause at Modus Delays Readout

KDventures
Press release15.10.2026, 07.45

KDventures portfolio company Modus Therapeutics temporarily pauses enrollment in Phase 2a study of sevuparin in chronic kidney disease with anemia

KDventures

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release07.10.2026, 13.00

KDventures portfolio company Umecrine Cognition invited to showcase Parkinson’s disease program and new translational data at The Michael J. Fox Foundation’s PDTC 2026

KDventures
Press release30.09.2026, 12.34

Redeye: KDventures: Impressive but Dilutive Equity Issue for AnaCardio

KDventures
Press release30.09.2026, 08.10

KDventures’ portfolio company AnaCardio raises EUR 62.5 million in Series B financing

KDventures
Press release15.09.2026, 08.30

KDventures’ portfolio company Umecrine Cognition reports last patient out in Phase 1b/2a study evaluating golexanolone in primary biliary cholangitis

KDventures
Press release07.09.2026, 18.04

Redeye: KDventures: Umecrine Secures NCE protection to 2042, unlocking broader commercial upside

KDventures
Press release07.09.2026, 09.05

KDventures’ portfolio company Umecrine Cognition receives two Notices of Allowance in the US for second-generation GAMSA compounds

KDventures
Press release04.09.2026, 13.05

KDventures portfolio company Modus Therapeutics carries out a directed issue of MSEK 7.6

KDventures
Regulatory press release28.08.2026, 08.00

Interim Report - January-June 2026

KDventures
Press release03.08.2026, 12.45

KDventures’ portfolio company Umecrine Cognition enrolls last patient in ongoing Phase 1b/2a study

KDventures
Press release09.07.2026, 16.45

KDventures’ portfolio company PharmNovo secures capital ahead of phase 2 study; holding written down

KDventures
Regulatory press release30.06.2026, 08.00

Change of number of shares and votes in KDventures AB

KDventures
Press release25.06.2026, 10.05

KDventures’ portfolio company AnaCardio’s clinical study of drug candidate AC01 published in The Lancet

KDventures
Regulatory press release23.06.2026, 14.05

KDventures’ portfolio company Umecrine Cognition completes interim sample size analysis in ongoing clinical study of golexanolone

KDventures
Regulatory press release18.06.2026, 08.15

KDventures AB has carried out a directed issue of a total of 99,516,667 new B shares and raises approximately SEK 23.9 million

KDventures
Regulatory press release17.06.2026, 19.40

KDventures AB explores the conditions for carrying out a directed issue

KDventures
Regulatory press release08.06.2026, 08.00

KDventures participates in portfolio company Umecrine Cognitions’ share issue and writes down book value

KDventures
Press release27.05.2026, 08.50

KDventures' portfolio company Umecrine Cognition presents new patient data identifying severe fatigue as the most burdensome symptom in PBC

KDventures